XML 45 R24.htm IDEA: XBRL DOCUMENT v3.22.4
Segment and Geographic Information
 12 Months Ended
Dec. 31, 2022
Segment Reporting [Abstract]  
Segment and Geographic Information
15.
Segment and Geographic Information

The Company has determined that the chief executive officer is the chief operating decision maker (“CODM”). The CODM reviews financial information presented for the Company’s various clinical trial programs as well as results on a consolidated basis. License revenues and development revenues received are not allocated to various programs for purposes of determining a profit measure and resource allocation decisions are made by the CODM based primarily on consolidated results. As such, the Company has concluded that it operates as one segment. Supplemental enterprise-wide information has been presented below.

Geographic Revenues

Geographic revenues, which are based on the region that revenue is generated, are as follows (in thousands):

 

 

 

Years Ended December 31,

 

 

 

2022

 

 

2021

 

 

2020

 

China

 

$

84,631

 

 

$

55,640

 

 

$

73,361

 

Europe

 

 

33,820

 

 

 

131,243

 

 

 

17,954

 

Japan

 

 

9,764

 

 

 

2,305

 

 

 

19,824

 

United States

 

 

12,519

 

 

 

46,121

 

 

 

65,180

 

Total revenue

 

$

140,734

 

 

$

235,309

 

 

$

176,319

 

Geographic Assets

Property and equipment, net by geographic location are as follows (in thousands):

 

 

 

December 31,

 

 

 

2022

 

 

2021

 

United States

 

$

10,094

 

 

$

15,002

 

China

 

 

10,511

 

 

 

13,275

 

Total property and equipment

 

$

20,605

 

 

$

28,277

 

 

Finance lease right-of-use assets and operating lease right-of-use assets, net by geographic location are as follows (in thousands):

 

 

 

December 31,

 

 

 

2022

 

 

2021

 

United States

 

$

424

 

 

$

730

 

China

 

 

11

 

 

 

31

 

Total finance lease right-of-use assets

 

$

435

 

 

$

761

 

 

 

 

 

 

 

 

United States

 

$

76,273

 

 

$

87,113

 

China

 

 

3,620

 

 

 

3,999

 

Total operating lease right-of-use assets

 

$

79,893

 

 

$

91,112

 

Customer Concentration

The Company’s revenues to date have been generated from the following collaboration partners and distribution entity that individually accounted for 10% or more of the Company’s total revenue or accounts receivable:

 

 

 

Percentage of Revenue

 

 

Percentage of Accounts Receivable

 

 

 

Years Ended December 31,

 

 

December 31,

 

 

 

2022

 

 

2021

 

 

2020

 

 

2022

 

 

2021

 

Falikang — Related party

 

 

51

%

 

 

15

%

 

 

—

%

 

 

65

%

 

 

—

%

Astellas — Related party

 

 

31

%

 

 

57

%

 

 

21

%

 

 

9

%

 

 

63

%

AstraZeneca

 

 

9

%

 

 

20

%

 

 

37

%

 

 

16

%

 

 

34

%

 

In January 2021, Falikang became fully operational and substantially all direct product sales to distributors in China were made by Falikang, while FibroGen Beijing continued to sell roxadustat product directly through pharmaceutical distributors in one province in China during 2021 and in one province in 2022. No individual distributor represented over 10% of the total revenue for the years ended December 31, 2022 and 2021. The aggregate accounts receivable from direct sales to distributors as of December 31, 2022 and 2021 were immaterial.

For the year ended December 31, 2020, the aggregate revenue from distributors represented 42% of the consolidated revenue, with no individual distributor representing over 10% of the total revenue. As of December 31, 2020, the aggregate accounts receivable from distributors represented 64% of the consolidated accounts receivable, with no material balance from any individual distributor.